Integrating 3HP‐based tuberculosis preventive treatment into Zimbabwe's Fast Track HIV treatment model: experiences from a pilot study

Author:

Mapingure Munyaradzi P.1,Zech Jennifer M.2ORCID,Hirsch‐Moverman Yael23,Msukwa Martin4ORCID,Howard Andrea A.23,Makoni Tatenda5,Gwanzura Clorata6,Apollo Tsitsi6,Sandy Charles6,Musuka Godfrey N.7ORCID,Rabkin Miriam23

Affiliation:

1. ICAP Zimbabwe Harare Zimbabwe

2. ICAP at Columbia University New York City New York USA

3. Department of Epidemiology Mailman School of Public Health Columbia University New York City New York USA

4. ICAP at Columbia University Pretoria South Africa

5. Zimbabwe Network for People Living with HIV (ZNNP+) Harare Zimbabwe

6. Ministry of Health and Child Care (MoHCC) Harare Zimbabwe

7. International Initiative for Impact Evaluation (3ie) New Delhi India

Abstract

AbstractIntroductionTuberculosis (TB) causes one‐third of HIV‐related deaths worldwide, making TB preventive treatment (TPT) a critical element of HIV programmes. Approximately 16% of people living with HIV (PLHIV) on antiretrovirals in Zimbabwe are enrolled in the Fast Track (FT) differentiated service delivery model, which includes multi‐month dispensing of antiretrovirals and quarterly health facility (HF) visits. We assessed the feasibility and acceptability of utilizing FT to deliver 3HP (3 months of once‐weekly rifapentine and isoniazid) for TPT by aligning TPT and HIV visits, providing multi‐month dispensing of 3HP, and using phone‐based monitoring and adherence support.MethodsWe recruited a purposive sample of 50 PLHIV enrolled in FT at a high‐volume HF in urban Zimbabwe. At enrolment, participants provided written informed consent, completed a baseline survey, and received counselling, education and a 3‐month supply of 3HP. A study nurse mentor called participants at weeks 2, 4 and 8 to monitor and support adherence and side effects. When participants returned for their routine 3‐month FT visit, they completed another survey, and study staff conducted a structured medical record review. In‐depth interviews were conducted with providers who participated in the pilot.ResultsParticipants were enrolled between April and June 2021 and followed through September 2021. Median age = 32 years (IQR 24,41), 50% female, median time in FT 1.8 years (IQR 0.8,2.7). Forty‐eight participants (96%) completed 3HP in 13 weeks; one completed in 16 weeks, and one stopped due to jaundice. Most participants (94%) reported “always” or “almost always” taking 3HP correctly. All reported they were very satisfied with the counselling, education, support and quality of care they received from providers and FT service efficiency. Almost all (98%) said they would recommend it to other PLHIV. Challenges reported included pill burden (12%) and tolerability (24%), but none had difficulty with phone‐based counselling or wished for additional HF‐based visits.DiscussionUsing FT to deliver 3HP was feasible and acceptable. Some reported tolerability challenges but 98% completed 3HP, and all appreciated the efficiency of aligning TPT and HIV HF visits, multi‐month dispensing and phone‐based counselling.ConclusionsScaling up this approach could expand TPT coverage in Zimbabwe.

Publisher

Wiley

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health

Reference32 articles.

1. World Health Organization.HIV‐associated TB.2018[cited 2022 Feb 12]https://www.who.int/tb/areas‐of‐work/tb‐hiv/tbhiv_factsheet.pdf?ua=1

2. PHIA Project.Zimbabwe Summary Sheet.2020[cited 2022 Nov 21]https://phia.icap.columbia.edu/zimbabwe‐2020‐summary‐sheet

3. World Health Organization.Tuberculosis profile: Zimbabwe. [Cited 2022 Nov 7]https://worldhealthorg.shinyapps.io/tb_profiles/?_inputs_&entity_type=%22country%22&lan=%22EN%22&iso2=%22ZW%22

4. Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3